Member Sign In

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

Boston Scientific (BSX) Reports Positive Data on HeartLogic

Boston Scientific Corporation (BSX - Free Report) recently announced positive results from the first clinical trial on the HeartLogic Heart Failure Diagnostic Service to evaluate impending heart failure (HF) decompensation. Data collected from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients (MultiSENSE) study were presented as a late-breaking clinical trial at the American Heart Association (AHA) Scientific Sessions 2016 in New Orleans.

The study included 900 patients who had improved sensor data collection enabled in their cardiac resynchronization therapy defibrillator (CRT-D) systems and were followed for up to one year in either a development or test cohort. Information from the 500 patients within the development set was used to construct the HeartLogic composite index and alert algorithm by combining heart sounds, respiration rate and volume, thoracic impedance, heart rate and activity. The 400 patients within the test set were sequestered for subsequent independent validation of HeartLogic.

The MultiSENSE trial data confirmed that HeartLogic alert had an observed sensitivity of 70% and a low unexplained alert rate (alerts not followed by a HF event) of 1.47 per patient per year. The data also demonstrated that the alert algorithm by combining multiple measurements could successfully inform clinicians of worsening heart failure and lay the foundation for future studies.

Notably, HeartLogic Heart Failure Diagnostic Service is not commercially available at present. Management has submitted a design profile for CE Mark and a premarket FDA approval application of the HeartLogic service and plans to carry out post-approval studies, including Multiple cArdiac seNsors for mAnaGEment of Heart Failure (MANAGE-HF), to further evaluate the alert. We expect this latest development to advance this process of approval.

As per a GlobalData report, the global heart failure market is set to grow to $11.8 billion by 2025, at a CAGR of 13.7%. We believe Boston Scientific has the means to cash in the opportunities in this growing market. In its recently concluded third quarter, Boston Scientific’s Medsurg and Rhythm Management segment posted a strong performance, recording a 10% growth. The HeartLogic service study results will boost the segment’s capabilities to develop differentiated solutions for the management of heart failure cases.

NxStage Medical surged 31.6% over the last one year compared to the S&P 500’s 6.3% over the same period. The company has a four-quarter average positive earnings surprise of 50.00%.

Baxter International rallied 20.9% in the past one year, much higher than the S&P 500’s 4.5%. It has a trailing four-quarter average positive earnings surprise of 27%.

Bovie Medical recorded a 126.5% gain in the past one year, way better than the S&P 500’s 4.5%. The company has a trailing four-quarter positive average earnings surprise of 28.7%.

Zacks' Top Investment Ideas for Long-Term Profit

How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>

Resources

Client Support

Follow Us

Zacks Moblie App

Zacks Research is Reported On:

Yahoo

MSN

Marketwatch

Nasdaq

Forbes

Investors.com

Morningstar

Copyright 2018 Zacks Investment Research

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +25% per year. These returns cover a period from 1988-2017. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zack Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

Visit performance for information about the performance numbers displayed above.